More specifically, investigators have found deguelin displays anti-cancer activities both in vitro and in vivo for a variety of cancers across tissue types, including non-small cell lung cancer [22,23,24,25], triple negative breast cancer [26,27], prostate cancer [28], gastric cancer [29,30,31], hepatocellular carcinoma [32,33], esophageal squamous cell carcinoma [34,35], acute myeloid leukemia [36,37,38,39], pancreatic cancer [40,41,42], head and neck squamous cell carcinoma [43,44,45], lung squamous cell carcinoma [46], and androgen receptor-positive breast cancer [47]. This evidence concerns the gene AR and squamous cell lung carcinoma.